BioXcel Therapeutics: Funding, Investors & Team (Sep 2026)
BioXcel Therapeutics is a clinical-stage biopharmaceutical company focused on drug development that utilizes novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. Its drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. They believe that this differentiated approach has the potential to reduce the cost and time of drug development in diseases with substantial unmet medical needs. BXCL501 is a sublingual thin film formulation of the a2a adrenergic receptor agonist dexmedetomidine, or Dex, for acute treatment of agitation resulting from neurological and psychiatric disorders. It intends to utilize the 505(b)(2) pathway for BXCL501, initiated a Phase 1b safety study using the IV formulation of Dex in mild probable Alzheimer's Disease in December 2017, and plans to do the same for schizophrenia patients in the 1H18, with data expected in the 2H18. BXCL701 (formerly Talabostat) is an immuno-oncology agent for the treatment of a rare form of prostate cancer and pancreatic cancer.
BioXcel Therapeutics has raised $8.0M across 1 funding round on record, the most recent an undisclosed round of $8.0M announced in Mar 2026.
That round is above the $5.5M median round size for Artificial Intelligence companies tracked on FundedIQ over the last two years.
BioXcel Therapeutics Company Profile and Key Stats
Latest funding round on record: Mar 2026.
BioXcel Therapeutics Funding Rounds
BioXcel Therapeutics Founders and Leadership Team
Contact details for the BioXcel Therapeutics team: 1 has a LinkedIn profile.
Start 14-day free trial →BioXcel Therapeutics Funding Compared to Other Artificial Intelligence Startups
BioXcel Therapeutics' latest round of $8.0M is above the median round in Artificial Intelligence. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like BioXcel Therapeutics in Artificial Intelligence and New Haven
Companies Similar to BioXcel Therapeutics
Socure is a predictive analytics platform for digital identity verification of consumers. Socure's predictive…
Instinct is an artificial intelligence startup developing AI technology.
Significant gives vehicle-mounted PC vision innovation that distinguishes visual deformities in network…
Cloverleaf AI exists to help you fill your pipeline with high-quality SLED leads. Tell us what you deliver,…
Emerald AI develops software and platforms that manage and coordinate energy use for artificial intelligence…
Gatik, a new company, is creating technology for self-driving trucks that are used for short-distance…
Generalist AI develops AI and robotics technologies focused on enabling robots to perform physical tasks in…
Quintessent is a start-up in Santa Barbara that specializes in bringing quantum dot-based lasers and photonic…
Contact: Cardiosense is building a physiological waveform data platform that leverages novel multi-modal…
Thunder is a Cloud computing to democratize access to GPUs and solve the ongoing GPU shortage. Decentralized…
Deepgram helps enterprises unlock the potential of their audio data with custom trained speech recognition…
BioXcel Therapeutics Funding FAQs
What does BioXcel Therapeutics do?
BioXcel Therapeutics is a clinical-stage biopharmaceutical company focused on drug development that utilizes novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. Its drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. They believe that this differentiated approach has the potential to reduce the cost and time of drug development in diseases with substantial unmet medical needs. BXCL501 is a sublingual thin film formulation of the a2a adrenergic receptor agonist dexmedetomidine, or Dex, for acute treatment of agitation resulting from neurological and psychiatric disorders. It intends to utilize the 505(b)(2) pathway for BXCL501, initiated a Phase 1b safety study using the IV formulation of Dex in mild probable Alzheimer's Disease in December 2017, and plans to do the same for schizophrenia patients in the 1H18, with data expected in the 2H18. BXCL701 (formerly Talabostat) is an immuno-oncology agent for the treatment of a rare form of prostate cancer and pancreatic cancer.
How much funding has BioXcel Therapeutics raised?
BioXcel Therapeutics has raised $8.0M across 1 round on record. The most recent is an undisclosed round of $8.0M announced in Mar 2026.
When did BioXcel Therapeutics last raise funding?
BioXcel Therapeutics' most recent funding round on record is an undisclosed round of $8.0M, announced in Mar 2026.
Who founded BioXcel Therapeutics?
FundedIQ lists Vimal Mehta (Founder) at BioXcel Therapeutics.
Where is BioXcel Therapeutics headquartered?
BioXcel Therapeutics is based in New Haven, Connecticut, United States.
How many employees does BioXcel Therapeutics have?
BioXcel Therapeutics is in the 51-100 employee band.
How does BioXcel Therapeutics' funding compare to other Artificial Intelligence startups?
BioXcel Therapeutics' latest round of $8.0M is above the $5.5M median round size for Artificial Intelligence companies on FundedIQ across 7,233 tracked companies over the last two years.
About FundedIQ's BioXcel Therapeutics Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for BioXcel Therapeutics is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.